Ashkan Emadi
Overview
Explore the profile of Ashkan Emadi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
1831
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kleckner A, Clingan C, Youngblood S, Kleckner I, Quick L, Elrod R, et al.
Res Sq
. 2025 Jan;
PMID: 39764090
Purpose: Time-restricted eating (TRE) helps regulate rest-activity rhythms, blood glucose, and other diurnally regulated energetics processes, which may have implications for persistent fatigue. In a randomized controlled trial, we tested...
2.
Bollino D, Ma X, Tighe K, Casildo A, Richard K, Passaniti A, et al.
Int J Mol Sci
. 2024 Dec;
25(23).
PMID: 39684800
Our previous studies have demonstrated that pegcrisantaspase (PegC), a long-acting asparaginase, synergizes with the BCL-2 inhibitor Venetoclax (Ven) in vitro and in vivo; however, the anti-leukemic activity of -derived asparaginases...
3.
Liu Y, Bollino D, Bah O, Strovel E, Le T, Le T, et al.
Blood
. 2024 Oct;
145(5):486-496.
PMID: 39437546
Glutamine dependency has been shown to be a metabolic vulnerability in acute myeloid leukemia (AML). Prior studies using several in vivo AML models showed that depletion of plasma glutamine, induced...
4.
Sanchez-Petitto G, Goloubeva O, Childress J, Iqbal T, Masur J, An M, et al.
Acta Haematol
. 2024 Aug;
:1-12.
PMID: 39191224
Introduction/background: Reduced-intensity conditioning (RIC) and nonmyeloablative (NMA) regimens have enabled patients with cardiovascular disease (CVD) to undergo allogeneic stem cell transplantation (allo-HSCT). However, little is known about long-term outcomes, including...
5.
Wieland L, Shade S, Moffet I, Ansari A, Emadi A, Knott C, et al.
Nutr Cancer
. 2024 Jul;
76(10):902-913.
PMID: 39078314
Introduction: The effects of antioxidant dietary supplements on response to biological therapies for cancer is unknown. We conducted a scoping review of the available systematic review evidence on this question....
6.
Bollino D, Hameed K, Bhat A, Zarrabi A, Casildo A, Ma X, et al.
Cancer Metab
. 2024 Jul;
12(1):19.
PMID: 38951899
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease without meaningful therapeutic options beyond the first salvage therapy. Targeting PDAC metabolism through amino acid restriction has emerged as a promising...
7.
Ramdas B, Dayal N, Pandey R, Larocque E, Kanumuri R, Pasupuleti S, et al.
J Clin Invest
. 2024 Jul;
134(12).
PMID: 38950330
Activating mutations of FLT3 contribute to deregulated hematopoietic stem and progenitor cell (HSC/Ps) growth and survival in patients with acute myeloid leukemia (AML), leading to poor overall survival. AML patients...
8.
Liu Y, Ning Y, Ghiaur G, Emadi A
Acta Haematol
. 2024 Jun;
148(1):111-118.
PMID: 38824913
Introduction: Acute promyelocytic leukemia (APL) is genetically characterized by the fusion of promyelocytic leukemia (PML) gene with retinoic acid receptor alpha (RARα) resulting from a t(15;17)(q24;q21) chromosomal translocation. An infrequent...
9.
Hameed K, Bollino D, Shetty A, Carter-Cooper B, Lapidus R, Emadi A
Front Oncol
. 2024 May;
14:1326754.
PMID: 38690164
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy characterized by disrupted blood cell production and function. Recent investigations have highlighted the potential of targeting glutamine metabolism as a promising...
10.
Kathari Y, An M, Dougherty C, Emadi A
Pharmaceuticals (Basel)
. 2024 Mar;
17(3).
PMID: 38543121
Older adults who are diagnosed with acute lymphoblastic leukemia (ALL) and are treated with chemotherapy generally have poor outcomes. Blinatumomab is a CD19/CD3 bispecific T-cell engager that has been approved...